BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
BioLineRx and partner Hemispherian announced positive preclinical data demonstrating strong synergy between GLIX1 and the PARP inhibitor olaparib in a patient-derived ovarian cancer model. The combination therapy showed tumor reduction comparable to the chemotherapy benchmark cisplatin and outperformed monotherapy arms, supporting the synthetic lethality mechanism in HR-proficient tumors.
Key figures
- Drug Name
- GLIX1
- Trial id
- NCT07464925
- Trial phase
- Phase 1/2a
- Hr proficient tumor pct
- 50%
- Ovarian cancer cases 2026
- approximately 21,000
- Ovarian cancer deaths 2026
- 12,450
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.